Track topics on Twitter Track topics that are important to you
Three of four proposals pass with shareholder approval
Annual Meeting adjourned solely with respect to Proposal 3 – approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock
ROCKVILLE, Md., June 14, 2018 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced that its 2018 Annual Meeting of Shareholders (the “Annual Meeting”), scheduled for Thursday, June 14, 2018, was convened and Proposals 1, 2 and 4, each as set forth in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 23, 2018 (the “Proxy Statement”), were approved.
The Company adjourned the Annual Meeting with respect to Proposal 3, a proposal to amend its amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000 shares. While Proposal 3 has received the support of the majority of shares voting on the proposal, approval of more than 50% of all outstanding shares of Rexahn common stock as of April 18, 2018 is necessary for the proposal to be approved. The adjournment will allow for the solicitation of additional votes on Proposal 3. The Annual Meeting will resume with respect to Proposal 3 at 8:00 a.m. EDT on Wednesday, June 27, 2018 at the Radisson Hotel, 3 Research Court, Rockville, Maryland 20850.
“Given that a majority of our voting shareholders are in favor of the proposal to increase the number of authorized shares, we believe it is important that shareholders who have yet to vote be provided additional time to vote,” said Peter D. Suzdak, Ph.D., chief executive officer of Rexahn. “We encourage those shareholders who have yet to vote to vote ‘for’ the proposal.”
During the pendency of the adjourned meeting, shareholders holding shares as of the record date of April 18, 2018 who have not yet voted are encouraged to vote on Proposal No. 3. Shareholders may also change their vote for Proposal No. 3 by executing a new proxy, revoking a previously given proxy or attending the meeting and voting in person, as set forth in the Proxy Statement. If you hold your shares in “street name” through a broker, bank or other nominee, you may vote via the Internet by going to www.proxyvote.com, while shareholders of record may go to www.aalvote.com/rnn to vote via the Internet. Only shareholders of record on the record date of April 18, 2018 are entitled and are being requested to vote. Shareholders are urged to read the proxy statement and other relevant documents filed with the SEC.
How to Vote
For assistance in voting your shares or for general inquiries please contact our proxy advisor:
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American:RNN) is a clinical stage biopharmaceutical company dedicated to developing novel, targeted therapeutics for the treatment of cancer. The Company's mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn's product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that certain of Rexahn's product candidates may be effective against multiple types of cancer, including drug resistant cancers, and difficult-to-treat cancers, and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development including RX-0201. For more information about the Company and its oncology programs, please visit www.rexahn.com.
To the extent any statements made in this press release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the adjourned annual meeting and other statements identified by words such as “will,” “potential,” “could,” “can,” “believe,” “intends,” “continue,” “plans,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause Rexahn’s actual results to be materially different than those expressed in or implied by Rexahn’s forward-looking statements. Rexahn undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Susan Forman or Laura Radocaj
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.